<code id='03EEEA74E4'></code><style id='03EEEA74E4'></style>
    • <acronym id='03EEEA74E4'></acronym>
      <center id='03EEEA74E4'><center id='03EEEA74E4'><tfoot id='03EEEA74E4'></tfoot></center><abbr id='03EEEA74E4'><dir id='03EEEA74E4'><tfoot id='03EEEA74E4'></tfoot><noframes id='03EEEA74E4'>

    • <optgroup id='03EEEA74E4'><strike id='03EEEA74E4'><sup id='03EEEA74E4'></sup></strike><code id='03EEEA74E4'></code></optgroup>
        1. <b id='03EEEA74E4'><label id='03EEEA74E4'><select id='03EEEA74E4'><dt id='03EEEA74E4'><span id='03EEEA74E4'></span></dt></select></label></b><u id='03EEEA74E4'></u>
          <i id='03EEEA74E4'><strike id='03EEEA74E4'><tt id='03EEEA74E4'><pre id='03EEEA74E4'></pre></tt></strike></i>

          
          WSS
          Sterile capsules for injection line up in a dispensing line — politics coverage from STAT
          Adobe

          WASHINGTON — The Senate Finance Committee has drafted a bipartisan bill to mitigate drug shortages by rewarding hospitals for business practices that ensure an adequate supply of drugs.

          Drug shortages have been a persistent problem for years, and they’re worse than ever, according to a recent report by the American Society of Health-System Pharmacists. Shortages are primarily a problem for hospitals and doctors who regularly administer drugs, including oncologists who have been running out of common chemo drugs. Generic injectables account for 67% of shortages, and more than half of drugs in short supply cost less than $1 per unit, according to the Finance Committee.

          advertisement

          Hospitals band together to negotiate drug prices by hiring group purchasing organizations. The biggest three GPOs are estimated to control about 90% of the market for drugs that hospitals buy. Finance Chair Ron Wyden (D-Ore.) said those GPOs can drive prices down so low that manufacturers stop making certain drugs or can’t afford to maintain their facilities, which then leads to manufacturing interruptions. Drugmakers also say GPOs can also be fickle, switching from one manufacturer to another over small savings, leaving drugmakers without the certainty they need to commit to making large volumes of product.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          entertainment